Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.02 and traded as high as $2.00. Cortexyme shares last traded at $1.85, with a volume of 168,423 shares changing hands.
Cortexyme Trading Up 0.5 %
The stock has a market cap of $55.78 million, a PE ratio of -0.62 and a beta of 1.40. The business’s 50-day moving average price is $1.57 and its 200-day moving average price is $1.02.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Stories
- Five stocks we like better than Cortexyme
- How to Use the MarketBeat Dividend Calculator
- Micron Stock Under $100: Seize the AI-Driven Upside
- Compound Interest and Why It Matters When Investing
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- Best Aerospace Stocks Investing
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
